MLchartDataset catalogue

Casirivimab

Term · Oncology and biomedicine · MLC-T-ONC-012329

A recombinant, human immunoglobulin G1 (IgG1) kappa monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab specifically targets and binds to the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.

Table 1. Record
IdentifierMLC-T-ONC-012329
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012329",
  "term": "Casirivimab",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant, human immunoglobulin G1 (IgG1) kappa monoclonal antibody directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab specifically targets and binds to the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/casirivimab/"
}

Record 4,305 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.